Your browser doesn't support javascript.
loading
Tricuspid Regurgitation and TAVR: Outcomes, Risk Factors and Biomarkers.
Puehler, Thomas; Pommert, Nina Sophie; Freitag-Wolf, Sandra; Seoudy, Hatim; Ernst, Markus; Haneya, Assad; Sathananthan, Janarthanan; Sellers, Stephanie L; Meier, David; Schöttler, Jan; Müller, Oliver J; Salehi Ravesh, Mona; Saad, Mohammed; Frank, Derk; Lutter, Georg.
Affiliation
  • Puehler T; Department of Cardiac and Vascular Surgery, University Medical Center Schleswig-Holstein, Campus Kiel, Arnold-Heller Strasse 3, D-24105 Kiel, Germany.
  • Pommert NS; DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, 23562 Lübeck, Germany.
  • Freitag-Wolf S; Department of Cardiac and Vascular Surgery, University Medical Center Schleswig-Holstein, Campus Kiel, Arnold-Heller Strasse 3, D-24105 Kiel, Germany.
  • Seoudy H; DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, 23562 Lübeck, Germany.
  • Ernst M; Institute of Medical Informatics and Statistics, University Medical Center Schleswig-Holstein, Campus Kiel, D-24105 Kiel, Germany.
  • Haneya A; Department of Internal Medicine III (Cardiology, Angiology, and Critical Care), University Medical Center Schleswig-Holstein, Campus Kiel, D-24105 Kiel, Germany.
  • Sathananthan J; Department of Cardiac and Vascular Surgery, University Medical Center Schleswig-Holstein, Campus Kiel, Arnold-Heller Strasse 3, D-24105 Kiel, Germany.
  • Sellers SL; Department of Cardiac and Vascular Surgery, University Medical Center Schleswig-Holstein, Campus Kiel, Arnold-Heller Strasse 3, D-24105 Kiel, Germany.
  • Meier D; Center for Heart Valve Innovation & Cardiovascular Translational Laboratory, St Paul's Hospital, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
  • Schöttler J; Center for Heart Valve Innovation & Cardiovascular Translational Laboratory, St Paul's Hospital, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
  • Müller OJ; Center for Heart Valve Innovation & Cardiovascular Translational Laboratory, St Paul's Hospital, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
  • Salehi Ravesh M; Department of Cardiac and Vascular Surgery, University Medical Center Schleswig-Holstein, Campus Kiel, Arnold-Heller Strasse 3, D-24105 Kiel, Germany.
  • Saad M; DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, 23562 Lübeck, Germany.
  • Frank D; Department of Internal Medicine III (Cardiology, Angiology, and Critical Care), University Medical Center Schleswig-Holstein, Campus Kiel, D-24105 Kiel, Germany.
  • Lutter G; Department of Radiology and Neuroradiology, University Medical Center Schleswig-Holstein, Campus Kiel, D-24105 Kiel, Germany.
J Clin Med ; 13(5)2024 Mar 04.
Article in En | MEDLINE | ID: mdl-38592316
ABSTRACT
Background. The significance of concomitant tricuspid regurgitation (TR) in the context of transcatheter aortic valve replacement (TAVR) remains unclear. This study aimed to analyze the severity of TR before and after TAVR with regard to short- and long-term survival and to analyze the influencing factors. Methods. In our retrospective analysis, TR before and after TAVR was examined and patients were classified into groups accordingly. Special attention was paid to patients with post-interventional changes in TR. Mortality after TAVR was considered the primary endpoint of the analysis and major complications according to the Valve Academic Research Consortium 3 (VARC3) were compared. Moreover, biomarkers and risk factors for worsening or improvement of TR through TAVR were analyzed. Results. Among 775 patients who underwent TAVR in our center between January 2009 and December 2019, 686 patients (89%) featured low- and 89 patients (11%) high-grade TR. High-grade pre-TAVR TR was associated with worse short- (30-day), mid- (2-year) and long-term survival up to 8 years. Even though in nearly half of the patients with high-grade TR the regurgitation improved within seven days after TAVR (n = 42/89), this did not result in a survival benefit for this subgroup. On the other hand, a worsening of low-grade TR was seen in more than 10% of the patients (n = 73/686), which was also associated with a worse prognosis. Predictors of worsening of TR after TAVR were adipositas, impaired right ventricular function and the presence of mild TR. Age, atrial fibrillation, COPD, impaired renal function and elevated cardiac biomarkers were risk factors for mortality after TAVR independent from the grade of TR. Conclusions. Not only pre-interventional, but also post-TAVR high-grade TR is associated with a worse prognosis after TAVR. TAVR can change concomitant tricuspid regurgitation, but improvement does not have any impact on short- and long-term survival. Worsening of TR after TAVR is possible and impairs the prognosis.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Clin Med Year: 2024 Document type: Article Affiliation country: Alemania

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Clin Med Year: 2024 Document type: Article Affiliation country: Alemania
...